A Validated Liquid-Liquid Extraction Method with Direct Injection of Hexane for Clopidogrel in Human Plasma Using UltraPerformance Convergence Chromatography (UPC2) and Xevo TQ-S

Significance of the Topic

Clopidogrel is a clinically important antiplatelet prodrug used to prevent atherosclerotic events. Monitoring its active metabolite in plasma presents analytical challenges due to low circulating levels. Developing sensitive and efficient bioanalytical methods is critical for pharmacokinetic studies and therapeutic monitoring.

Objectives and Study Overview

This study aimed to develop and validate a highly sensitive liquid-liquid extraction (LLE) method with direct injection of hexane extracts into ultra-performance convergence chromatography (UPC2)/MS/MS for quantifying clopidogrel in human plasma. The approach eliminates evaporation and reconstitution steps, streamlining sample preparation and enhancing throughput.

Methodology

Sample Preparation:

• 200 µL human plasma mixed with 20 µL deuterated internal standard.
• Extraction with 600 µL hexane, vortex mixing, centrifugation.
• Supernatant directly transferred to LC vial; 10 µL injected.

Chromatographic Conditions:

• ACQUITY UPC2 BEH 3.0×100 mm, 1.7 µm column at 40 °C.
• Linear gradient from 98:2 to 70:30 CO2/0.1% formic acid in acetonitrile over 2 min at 1.4 mL/min.

Mass Spectrometry:

• Xevo TQ‐S operated in positive electrospray MRM mode.
• Transitions: m/z 322→12 for clopidogrel, 326→16 for d4 internal standard.

Instrumentation Used

• ACQUITY UPC2 System.
• Xevo TQ‐S Mass Spectrometer.

Main Results and Discussion

Clopidogrel eluted at approximately 1.6 min with a narrow peak width (~3 s) and minimal background. The signal-to-noise ratio at the lower limit of quantification (LLOQ, 25 pg/mL) was ~60:1. No carryover was observed after high‐concentration injections. Calibration curves were linear from 25 to 5000 pg/mL (r2 ≥ 0.996) with 1/x weighting. Intra-day precision (CV) ranged from 1.8% to 6.3% at LLOQ and bias within ±13.2%. Inter-day precision at LLOQ showed CV of 11.1% and bias of –2.0%; high QC (3750 pg/mL) CV 6.2%, bias 2.0%.

Benefits and Practical Applications

• High sensitivity suitable for low-level clopidogrel quantification.
• Simplified workflow by eliminating extract evaporation and reconstitution.
• Reduced solvent consumption and faster turnaround.
• Robust performance with minimal carryover benefits bioanalytical labs and clinical studies.

Future Trends and Applications

Potential developments include integrating convergence chromatography with high‐throughput platforms, expanding to other drug analytes, adopting greener extraction solvents, and combining with next‐generation mass spectrometers for enhanced sensitivity and throughput.

Conclusions

A validated UPC2/MS/MS assay with direct hexane extract injection delivers high sensitivity, precision, and accuracy for clopidogrel quantification in human plasma. The streamlined LLE workflow improves efficiency and is well-suited to bioanalytical and clinical environments.

References

• Pereillo JM, et al. Drug Metabolism and Disposition. 2002;30:1288–1295.
• Bongfiglio R, et al. Rapid Commun Mass Spectrom. 1999;13:1175–1185.